Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Upwork Inc (UPWK) vs Viatris Inc (VTRS) Price & Performance

Upwork IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Upwork Inc vs Viatris Inc — how do they compare? Upwork Inc trades at $8.6 (market cap $1.07B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 18.7× Upwork Inc's market cap, and Viatris Inc pays a 2.75% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Upwork Inc for 38 Days and Viatris Inc for 57 Days on average.

UPWKVTRS
Market Cap
$1.07B$20.03B
Volume
2,574,13014,109,977
Sector
IndustrialsHealth
52-Week High
$22.11$18.27
52-Week Low
$7.84$9.74
Typical Hold Time
38 Days57 Days
Enterprise Value
$833.01M$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Upwork Inc

UPWK trades at $8.57, up 2.02% today, but the technical outlook is bearish with resistance near $9. The company reported Q2 2026 earnings that beat estimates, with revenue of $191.7M and adjusted EBITDA of $64.1M (MarketBeat, August 10, 2026), but issued weak guidance causing a 13% stock drop (Invezz, August 11, 2026). Fundamentals show strong profitability with a 77.21% gross margin and a P/E of 10.99, though net income declined to $115.43M in 2025 from $216M in 2024.

The stock presents a mixed outlook: valuation appears attractive with analyst consensus target of $9.64 (12.5% upside), but risks include AI-driven disruption to freelance demand, insider selling, and ongoing securities fraud investigations (GlobeNewswire, September 2026). Investor sentiment is cautious despite a majority buy rating from analysts.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

UPWK

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Upwork Inc

Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.

Read more on UPWK →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →